Clinical trials: Asthma Patients
Asthma
Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)
This is a multicenter study to evaluate the efficacy and safety of MK0476 versus placebo in participants with chronic asthma who actively smoke cigarettes.
- Trial name
- NCT00284856
- Testing
- montelukast sodium, Comparator: fluticasone
- Volunteers
- 1,640 people
- Sponsor
- Organon and Co
Asthma
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1.
- Trial name
- NCT00482508
- Testing
- Omalizumab
- Volunteers
- 95 people
- Sponsor
- Novartis
Asthma
Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting
This is an open-label, multi-center, PMS study to observe the safety and effectiveness of ARNUITY administered in asthma subjects in a real world setting.
- Trial name
- NCT03595930
- Testing
- Arnuity
- Where
- South Korea
- Volunteers
- 668 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids
This is a randomized, double-blind, placebo-controlled study to evaluate the effects of lebrikizumab in patients with asthma who remain inadequately controlled while on chronic therapy with inhaled corticosteroids (ICS).
- Trial name
- MILLY (NCT00930163)
- Testing
- lebrikizumab (MILR1444A)
- Volunteers
- 218 people
- Sponsor
- Genentech, Inc.
Asthma
Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®
The primary objective of the study is to establish whether budesonide/formoterol fumarate dihydrate (BF) Spiromax 160/4.5 micrograms (mcg) is as effective as Symbicort Turbohaler 200/6 mcg administered twice daily in participants…
- Trial name
- NCT01803555
- Testing
- Budesonide/Formoterol SPIROMAX®, SYMBICORT® TURBOHALER®
- Where
- 114 sites in Austria, Belgium and 14 more
- Volunteers
- 605 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Bronchial Asthma
Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma
To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus fluticasone propionate DPI 50µg 1 inhalation bid in…
- Trial name
- NCT00448435
- Testing
- GW815SF HFA MDI, salmeterol and fluticasone propionate
- Where
- 8 sites in Japan
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Asthma
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
- Trial name
- SITAR (NCT01591044)
- Testing
- R940343 1mg, R940343 2mg
- Where
- 59 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Rigel Pharmaceuticals
Asthma
A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma
The study is aimed at evaluating efficacy and safety of oglemilast in the treatment of stable mild to moderate persistent asthma. The study involves two weeks of run in period. This is a placebo controlled study.
- Trial name
- NCT00859404
- Testing
- oglemilast
- Where
- India
- Volunteers
- 282 people
- Sponsor
- Glenmark Pharmaceuticals Europe Ltd. (R&D)
Asthma
Prevalence and Reversibility of Lung Hyperinflation in Asthma
The aim of this observational study is to evaluate the pulmonary hyperinflation and its immediate reversibility to a short acting beta2 agonist test in uncontrolled persistent asthmatic patients with dyspnea.
- Trial name
- Dist'air2 (NCT01573364)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study in Patients With Asthma
The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug.
- Trial name
- NCT00215358
- Testing
- Formoterol Fumarate
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dey
Asthma
Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma.
- Trial name
- NCT01641081
- Testing
- Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose
- Where
- 29 sites in United States
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Asthma
A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL
A multi-center, Phase IIb, double-blind, randomized, placebo controlled, parallel-group, repeated-dose study in male and female patients with moderate to severe asthma in which patients will be stabilized on AEROVANT then doses…
- Trial name
- NCT00801853
- Testing
- Aerovant
- Where
- 71 sites in United States, Hungary and 2 more
- Volunteers
- 424 people
- Sponsor
- Aerovance, Inc.
Asthma
A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics
The study is designed to look at the safety, tolerability and efficacy of 2 different doses of the study drug (CHF6001, a PDE4 inhibitor) in asthmatics, when given by inhalation, once a day for 9 days.
- Trial name
- CHF6001_POC2 (NCT01689571)
- Testing
- CHF6001
- Where
- 3 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Mild Asthma
Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd
This is a pharmacodynamic bioequivalence bronchoprovocation study using single-dose, double-blind, double-dummy, randomized, study consisting of four study treatments (zero dose [Placebo], E.Q.
- Trial name
- NCT06618105
- Testing
- Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations
- Where
- India
- Volunteers
- 144 people
- Sponsor
- Macleods Pharmaceuticals Ltd
Asthma
A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients
The primary objectives of this study are: i. to determine the effect of single oral doses (20 and 200 mg) of ONO-6950 versus placebo on exercise induced bronchoconstriction (EIB) as percent attenuation in the decrease of forced…
- Trial name
- NCT01536041
- Testing
- ONO-6950, Montelukast
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ono Pharma USA Inc
Asthma; Eosinophilic
Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
The purpose of this phase III Study is to demonstrate the efficacy of at least one dose of CHF 6532 on moderate and severe asthma exacerbations rate compared to placebo.
- Trial name
- PERSEA (NCT04049175)
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Bulgaria
- Volunteers
- 810 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate
Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether 5-days of treatment with fluticasone propionate protects the lung from responding to the AMP in this way.
- Trial name
- NCT00400855
- Testing
- Fluticasone propionate
- Where
- 2 sites in New Zealand
- Volunteers
- 49 people
- Sponsor
- GlaxoSmithKline
Asthma
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg…
- Trial name
- TRIGGER (NCT02676089)
- Testing
- CHF 5993 200/6/12.5 µg, CHF 1535 200/6 µg, CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
- Where
- 244 sites in Argentina, Belarus and 15 more
- Volunteers
- 1,437 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma-COPD Overlap Syndrome
A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China
To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.
- Trial name
- NCT02600221
- Where
- 13 sites in China
- Volunteers
- 2,016 people
- Sponsor
- AstraZeneca